Literature DB >> 19741228

Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.

Werner Wenning1, Aiden Haghikia, Jörg Laubenberger, David B Clifford, Peter F Behrens, Andrew Chan, Ralf Gold.   

Abstract

We describe the clinical and therapeutic course of a 52-year-old patient with multiple sclerosis in whom progressive multifocal leukoencephalopathy (PML) developed after 12 months of therapy with natalizumab. The patient was hospitalized 2 months after the onset of neurologic and psychiatric symptoms and was treated with plasma exchange and immunoadsorption to eliminate natalizumab. After a brief improvement, he became critically ill with an apparent episode of immune reconstitution inflammatory syndrome. Steroid-pulse therapy led to stabilization of the patient's condition and clinically significant recovery. This case illustrates that prompt diagnosis and treatment may improve the outcome in patients with severe PML associated with natalizumab therapy. 2009 Massachusetts Medical Society

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19741228     DOI: 10.1056/NEJMoa0810257

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  54 in total

1.  [Immune reconstitution syndrome].

Authors:  D Meyer-Olson; D Ernst; M Stoll
Journal:  Z Rheumatol       Date:  2012-04       Impact factor: 1.372

Review 2.  Progressive multifocal leukoencephalopathy and newer biological agents.

Authors:  Joseph R Berger
Journal:  Drug Saf       Date:  2010-11-01       Impact factor: 5.606

Review 3.  Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.

Authors:  Chen S Tan; Igor J Koralnik
Journal:  Lancet Neurol       Date:  2010-04       Impact factor: 44.182

4.  Prophylactic antiepileptic treatment reduces seizure frequency in natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  Robert Hoepner; Stefanie Dahlhaus; Susanne Kollar; Barbara Zurawski; Andrew Chan; Ingo Kleiter; Ralf Gold; Kerstin Hellwig
Journal:  Ther Adv Neurol Disord       Date:  2014-01       Impact factor: 6.570

5.  Integrin targeted therapeutics.

Authors:  Melissa Millard; Srinivas Odde; Nouri Neamati
Journal:  Theranostics       Date:  2011-02-17       Impact factor: 11.556

Review 6.  Managing MS in a changing treatment landscape.

Authors:  Martin Duddy; Aiden Haghikia; Eleonora Cocco; Christian Eggers; Jelena Drulovic; Olga Carmona; Helene Zéphir; Ralf Gold
Journal:  J Neurol       Date:  2011-03-25       Impact factor: 4.849

Review 7.  [Demyelinating disorders].

Authors:  T Weber; W Köhler
Journal:  Nervenarzt       Date:  2010-04       Impact factor: 1.214

8.  Treatment of refractory epilepsy with natalizumab in a patient with multiple sclerosis. Case report.

Authors:  Stefano Sotgiu; Maria R Murrighile; Gabriela Constantin
Journal:  BMC Neurol       Date:  2010-09-23       Impact factor: 2.474

Review 9.  Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.

Authors:  Clemens Warnke; Heinz Wiendl; Hans-Peter Hartung; Olaf Stüve; Bernd C Kieseier
Journal:  Drug Des Devel Ther       Date:  2010-07-21       Impact factor: 4.162

10.  Progressive multifocal leukoencephalopathy in a patient without apparent immunosuppression.

Authors:  Christos Vaklavas; Elsa P Sotelo-Rafiq; Jordan Lovy; Miguel A Escobar; Apostolia M Tsimberidou
Journal:  Virol J       Date:  2010-09-28       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.